Search

everythinglearnresearchcommunity

for

Search:↓

Microneedling with PRP is a safe and effective way to treat chronic alopecia areata, improving hair regrowth with minimal side effects.

Diphencyprone treatment protocols could be simplified as no harm occurred despite not fully following them.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Trichoscopy is useful for diagnosing and monitoring alopecia areata treatment.

The 60-second timed hair count is a reliable and simple way to measure hair shedding at home, showing older women tend to shed more hair than younger women.

Topical rosuvastatin and melatonin creams significantly reduce psoriasis severity and are safe.

Dupilumab is effective and safe for treating moderate-to-severe atopic dermatitis in adolescents.

People with alopecia areata often have lower vitamin D levels than healthy people.

Oral Apremilast effectively treats alopecia areata in most patients.

BM-PHA is as effective and safe as Restylane Perlane for improving nasolabial folds with minor side effects.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Tofacitinib may help treat severe hair loss, but more research is needed.

Traction alopecia is more common in African women than girls, especially when traction is applied to chemically relaxed hair; avoiding such hairstyles may reduce the risk.

Baricitinib is effective and safe for treating severe alopecia areata.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Alopecia areata severity and treatment response are linked to specific cytokine levels.

Testosterone may influence COVID-19 severity and outcomes.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Experts agreed on guidelines to improve research on Frontal Fibrosing Alopecia.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

People with alopecia areata often have lower vitamin D levels, which may be linked to the condition's severity.

Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.

Monthly PRP therapy is more effective than daily minoxidil for alopecia areata.

There are significant gaps and inconsistencies in diagnosing and treating alopecia areata in Greece and Italy.

Topical corticosteroids may be a safe and effective treatment for severe alopecia areata in children.

The study concluded that different treatments reduced post-COVID symptoms over time and that factors like age, severity, and comorbidities affect symptom risk.

Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.